Complement activation in patients with post-acute sequelae after SARS-CoV-2 infection
By
Madlene Holmqvist
Dick J. Sjöström
Katherine Carlson
Birgitta Gullstrand
Anders A. Bengtsson
Robin Kahn
Tom E. Mollnes
Per Åkesson
Per H. Nilsson
Fredrik Kahn
May 13, 2026
Clinical Scorecard: Complement System Activation in Individuals Experiencing Post-Acute Sequelae Following SARS-CoV-2 Infection
At a Glance
Category Detail
Condition Key Mechanisms Target Population Individuals aged ≥18 years with a history of SARS-CoV-2 infection and symptoms lasting for a minimum of 12 weeks. Care Setting
Key Highlights
PASC affects approximately one in eight individuals infected with SARS-CoV-2. Common symptoms include fatigue, dyspnoea, and cognitive dysfunction. No significant differences in complement activation markers were found between PASC patients and controls, indicating a need for further research. Guideline-Based Recommendations
Diagnosis
Management
Symptom management, follow-up assessments at 6-12 months post-infection, and consideration of interdisciplinary care. Monitoring & Follow-up
Risks
Patient & Prescribing Data
No compelling evidence of complement system activation in patients with PASC, suggesting alternative pathways may be involved.
Clinical Best Practices
Conduct thorough assessments of symptoms and quality of life in PASC patients. Utilize established diagnostic criteria for SARS-CoV-2 infection. Consider interdisciplinary approaches for comprehensive management of PASC. Related Resources & Content
